DE60331584D1 - Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen - Google Patents
Modifizierte natriuretic verbindungen, konjugate und ihre verwendungenInfo
- Publication number
- DE60331584D1 DE60331584D1 DE60331584T DE60331584T DE60331584D1 DE 60331584 D1 DE60331584 D1 DE 60331584D1 DE 60331584 T DE60331584 T DE 60331584T DE 60331584 T DE60331584 T DE 60331584T DE 60331584 D1 DE60331584 D1 DE 60331584D1
- Authority
- DE
- Germany
- Prior art keywords
- conjugates
- compounds
- disclosed
- natriuretic
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L2203/00—Applications
- C08L2203/02—Applications for biomedical use
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Hospice & Palliative Care (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42915102P | 2002-11-26 | 2002-11-26 | |
| PCT/US2003/037996 WO2004047871A2 (en) | 2002-11-26 | 2003-11-12 | Modified naturetic compounds, conjugates, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE60331584D1 true DE60331584D1 (de) | 2010-04-15 |
Family
ID=32393512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60331584T Expired - Lifetime DE60331584D1 (de) | 2002-11-26 | 2003-11-12 | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7662773B2 (de) |
| EP (1) | EP1569683B1 (de) |
| JP (1) | JP2006515579A (de) |
| CN (1) | CN100558398C (de) |
| AT (1) | ATE459370T1 (de) |
| AU (2) | AU2003297583B2 (de) |
| BR (1) | BR0316560A (de) |
| CA (1) | CA2504287A1 (de) |
| DE (1) | DE60331584D1 (de) |
| HK (1) | HK1087327A1 (de) |
| PL (1) | PL377813A1 (de) |
| SG (1) | SG159387A1 (de) |
| WO (1) | WO2004047871A2 (de) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7524635B2 (en) * | 2003-04-17 | 2009-04-28 | Biosite Incorporated | Methods and compositions for measuring natriuretic peptides and uses thereof |
| AU2003268531A1 (en) * | 2002-09-06 | 2004-03-29 | University Of South Florida | Materials and methods for treatment of allergic diseases |
| US20080214437A1 (en) * | 2002-09-06 | 2008-09-04 | Mohapatra Shyam S | Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases |
| US20060110359A1 (en) * | 2002-09-06 | 2006-05-25 | Juan Sanchez-Ramos | Cellular delivery of natriuretic peptides |
| DE60331584D1 (de) | 2002-11-26 | 2010-04-15 | Biocon Ltd | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen |
| US7648962B2 (en) * | 2002-11-26 | 2010-01-19 | Biocon Limited | Natriuretic compounds, conjugates, and uses thereof |
| JP4880461B2 (ja) | 2003-08-13 | 2012-02-22 | バイオコン・リミテッド | 治療薬用のマイクロ粒子脂肪酸塩固体製剤 |
| EP1727556A2 (de) * | 2004-02-17 | 2006-12-06 | University Of South Florida | Material und methoden zur behandlung von entzündlichen erkrankungen und zellproliferationsstörungen |
| EP3404102B1 (de) | 2004-04-21 | 2021-08-11 | Alexion Pharmaceuticals, Inc. | Knochenfreisetzungskonjugate und verfahren zur verwendung davon zum zielen von proteinen auf knochen |
| WO2006005140A2 (en) | 2004-07-15 | 2006-01-19 | The University Of Queensland | Proteinaceous compounds and uses therefor |
| US20080207505A1 (en) * | 2005-01-12 | 2008-08-28 | James Kenneth D | Bna Conjugates and Methods of Use |
| US7300494B2 (en) * | 2005-02-24 | 2007-11-27 | Hamilton Sundstrand Corporation | On-board inert gas generation system with compressor surge protection |
| HUE026231T2 (en) | 2005-04-07 | 2016-06-28 | Cardiorentis Ag | Use of a natriuretic peptide for the treatment of heart failure |
| RS53847B1 (en) | 2005-07-29 | 2015-08-31 | Nektar Therapeutics | PROCEDURES FOR OBTAINING POLYMER REAGENTS |
| US7803901B2 (en) | 2005-09-16 | 2010-09-28 | Mayo Foundation For Medical Education And Research | Polypeptides with natriuresis activity |
| US8759290B2 (en) * | 2005-10-18 | 2014-06-24 | Biocon Limited | Oral glucagon-like peptide conjugates for metabolic diseases |
| AU2007233123A1 (en) | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Linear natriuretic peptide constructs |
| WO2007115175A2 (en) | 2006-03-30 | 2007-10-11 | Palatin Technologies, Inc. | Cyclic natriuretic peptide constructs |
| EP2051585A4 (de) * | 2006-04-28 | 2010-06-02 | Univ South Florida | Materialien und verfahren zur unterdrückung von entzündungen durch hemmung des vorhof-rezeptors für natriuretische peptide |
| DK2687223T3 (en) | 2006-05-30 | 2017-10-23 | Mayo Foundation | Detection and treatment of dementia |
| EP2687223B1 (de) | 2006-05-30 | 2017-07-12 | Mayo Foundation For Medical Education And Research | Erkennung und Behandlung von Demenz |
| WO2007143561A1 (en) | 2006-06-01 | 2007-12-13 | Mayo Foundation For Medical Education And Research | Immunity to folate receptors |
| WO2008088582A2 (en) | 2006-08-04 | 2008-07-24 | Mayo Foundation For Medical Education And Research | Methods and materials related to trail isoforms |
| CA2662453A1 (en) * | 2006-09-08 | 2008-03-13 | Mayo Foundation For Medical Education And Research | Aquaretic and natriuretic polypeptides lacking vasodilatory activity |
| US8728532B2 (en) | 2007-04-12 | 2014-05-20 | Regents Of The University Of Minnesota | Ischemia/reperfusion protection compositions and methods of using |
| KR20080098216A (ko) * | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 |
| JP2011504506A (ja) | 2007-11-21 | 2011-02-10 | バイオマリン ファーマシューティカル インコーポレイテッド | Ｃ型ナトリウム利尿ペプチドの変異体 |
| WO2009156481A1 (en) * | 2008-06-25 | 2009-12-30 | Ascendis Pharma As | Pegylated bnp |
| EP2898900B1 (de) | 2008-09-19 | 2017-11-15 | Nektar Therapeutics | Polymerkonjugate von Ziconotid |
| US8449872B2 (en) | 2008-09-19 | 2013-05-28 | Nektar Therapeutics | Polymer conjugates of nesiritide peptides |
| CA2758581C (en) | 2009-05-20 | 2022-06-14 | Biomarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
| WO2011005939A2 (en) | 2009-07-09 | 2011-01-13 | Mayo Foundation For Medical Education And Research | Long acting atrial natriuretic peptide (la-anp) and methods for use thereof |
| CA2768810C (en) | 2009-07-23 | 2014-05-20 | Igisu Co., Ltd. | Skin external-preparation composition |
| WO2011136744A1 (en) | 2010-04-27 | 2011-11-03 | Agency For Science, Technology And Research | Eif4e binding peptides |
| WO2012013597A1 (de) * | 2010-07-28 | 2012-02-02 | Justus-Liebig-Universität Giessen | Stoffe und deren verwendung zur beeinflussung natriuretischer peptidrezeptoren |
| CA2823066A1 (en) | 2010-12-27 | 2012-07-05 | Alexion Pharma International Sarl | Compositions comprising natriuretic peptides and methods of use thereof |
| EP2678002A2 (de) | 2011-02-25 | 2014-01-01 | Medtronic, Inc. | Therapie für nierenerkrankungen und/oder herzinsuffizienz |
| US20140072557A1 (en) | 2011-02-28 | 2014-03-13 | National Cerebral And Cardiovascular Center | Medicinal agent for suppressing malignant tumor metastasis |
| US10184942B2 (en) | 2011-03-17 | 2019-01-22 | University Of South Florida | Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer |
| KR20140054084A (ko) | 2011-08-19 | 2014-05-08 | 도쿠리츠교세이호진 고쿠리츠쥰칸키뵤 겐큐센터 | 나트륨 이뇨 펩티드 수용체 gc-a 아고니스트 및 gc-b 아고니스트를 조합하여 이루어지는 악성 종양의 악화 방지용 의약 |
| WO2013032784A1 (en) | 2011-08-30 | 2013-03-07 | Mayo Foundation For Medical Education And Research | Natriuretic polypeptides |
| EP2750697A4 (de) | 2011-09-02 | 2015-03-25 | Medtronic Inc | Chimäre natriuretische peptidzusammensetzungen und verfahren zu ihrer herstellung |
| WO2013058833A1 (en) | 2011-10-19 | 2013-04-25 | Enobia Canada Limited Partnership | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| WO2013103896A1 (en) | 2012-01-06 | 2013-07-11 | Mayo Foundation For Medical Education And Research | Treating cardiovascular or renal diseases |
| US20150315259A1 (en) * | 2012-03-19 | 2015-11-05 | Madeleine Phamaceuticals Pty Ltd | Method of producing a recombinant peptide |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| TW201442721A (zh) | 2013-01-23 | 2014-11-16 | Daiichi Sankyo Co Ltd | 糖鏈修飾心房利尿鈉肽 |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| US10449236B2 (en) | 2014-12-05 | 2019-10-22 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| JPWO2016194855A1 (ja) * | 2015-05-29 | 2018-06-07 | 株式会社 イギス | 環状ペプチド並びに該環状ペプチドを含む医薬、外用剤および化粧料 |
| WO2017031114A1 (en) | 2015-08-17 | 2017-02-23 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
| WO2017058822A1 (en) | 2015-09-28 | 2017-04-06 | Alexion Pharmaceuticals, Inc. | Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia |
| US11400140B2 (en) | 2015-10-30 | 2022-08-02 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
| MX2018008050A (es) | 2016-01-08 | 2018-08-23 | Ascendis Pharma Growth Disorders As | Agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada con estabilidad endopeptidasa neutral (nep) incrementada. |
| EP3400022A1 (de) * | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Cnp-agonisten mit kontrollierter freisetzung mit niedriger anfänglicher npr-b-aktivität |
| EP3400019B1 (de) * | 2016-01-08 | 2022-09-28 | Ascendis Pharma Growth Disorders A/S | Cnp-prodroge mit trägerbefestigung am zylischen teil des peptids |
| CA3008017C (en) * | 2016-01-08 | 2024-01-02 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with reduced side-effects |
| WO2017118693A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| KR102518217B1 (ko) | 2016-01-08 | 2023-04-04 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제 |
| EP3426286A4 (de) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | Verfahren zur behandlung von hypophosphatasie bei kindern |
| EP3436020A4 (de) | 2016-04-01 | 2019-12-25 | Alexion Pharmaceuticals, Inc. | Verfahren zur behandlung von hypophosphatasie bei jugendlichen und erwachsenen |
| JP2019513711A (ja) | 2016-04-01 | 2019-05-30 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼによって筋力低下を治療すること |
| EP3464573A4 (de) | 2016-06-06 | 2020-02-19 | Alexion Pharmaceuticals, Inc. | Auswirkungen von metallen auf die herstellung von alkalischen phosphatasen |
| EP3500289A4 (de) | 2016-08-18 | 2020-05-06 | Alexion Pharmaceuticals, Inc. | Verfahren zur behandlung von tracheobronchomalazie |
| US10307398B2 (en) | 2016-09-20 | 2019-06-04 | Regents Of The University Of Minnesota | Resuscitation composition and methods of making and using |
| RS64203B1 (sr) | 2016-09-29 | 2023-06-30 | Ascendis Pharma Growth Disorders As | Kombinovana terapija sa agonistima cnp sa kontrolisanim oslobađanjem |
| US11072642B2 (en) | 2016-11-09 | 2021-07-27 | Mayo Foundation For Medical Education And Research | MANP analogues |
| MX2019010960A (es) * | 2017-03-22 | 2020-01-20 | Pharmain Corp | Agonistas del receptor natriuretico a (npra), composiciones y usos de los mismos. |
| AU2018243320A1 (en) | 2017-03-31 | 2019-10-10 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (HPP) in adults and adolescents |
| AU2018328209A1 (en) | 2017-09-05 | 2020-04-23 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| AU2018328208A1 (en) | 2017-09-05 | 2020-04-23 | Torque Therapeutics, Inc. | Reversible linkers and use thereof |
| KR102546103B1 (ko) | 2018-03-20 | 2023-06-21 | 니치유 가부시키가이샤 | 분기형 단분산 폴리에틸렌 글리콜, 중간체 및 그 제조 방법 |
| EP3773684A1 (de) | 2018-03-30 | 2021-02-17 | Alexion Pharmaceuticals, Inc. | Herstellung von glycoproteinen |
| KR102022118B1 (ko) * | 2019-01-07 | 2019-09-18 | 주식회사 아스트로젠 | 중추신경계 질환의 예방 또는 치료용 세린 유도체 화합물 |
| CN110278941B (zh) * | 2019-07-11 | 2021-05-28 | 西安国际医学中心有限公司 | 一种含有钠尿肽的离体心脏保护液 |
| CN111848776B (zh) * | 2020-08-31 | 2022-03-18 | 江苏璟泽生物医药有限公司 | 聚乙二醇修饰的rhBNP及其制备方法 |
| CN111978390B (zh) * | 2020-08-31 | 2022-10-14 | 上海景泽生物技术有限公司 | 聚乙二醇修饰的rhBNP及其用途 |
| WO2023039392A1 (en) * | 2021-09-07 | 2023-03-16 | Mayo Foundation For Medical Education And Research | Methods and materials for determining pgc target dosage |
| CN114316020A (zh) * | 2021-12-28 | 2022-04-12 | 南京岚煜生物科技有限公司 | 一种bnp重组蛋白及其制备方法和应用 |
Family Cites Families (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4044196A (en) * | 1972-03-30 | 1977-08-23 | Bayer Aktiengesellschaft | Crosslinked copolymers of α,β-olefinically unsaturated dicarboxylic anhydrides |
| US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| EP0083367A1 (de) * | 1981-07-02 | 1983-07-13 | WALTON, Alan G. | Glykosaminglykan arzneimittelkomplexe |
| ATE37983T1 (de) | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
| US4569794A (en) * | 1984-12-05 | 1986-02-11 | Eli Lilly And Company | Process for purifying proteins and compounds useful in such process |
| US5037741A (en) * | 1986-08-18 | 1991-08-06 | The Coca Cola Company | Enzymatic method for the synthesis and separation of peptides |
| JP2544929B2 (ja) * | 1987-06-17 | 1996-10-16 | 第一化学薬品 株式会社 | 新規生理活性ペプチド |
| US5114923A (en) | 1988-05-31 | 1992-05-19 | California Biotechnology Inc. | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
| CA1339210C (en) * | 1988-05-31 | 1997-08-05 | John Lewicki | Recombinant techniques for production of novel natriuretic and vasodilator peptides |
| JP2539665B2 (ja) * | 1988-06-20 | 1996-10-02 | 日本臓器製薬株式会社 | 神経疾患治療剤 |
| JP2561513B2 (ja) | 1988-07-04 | 1996-12-11 | 塩野義製薬株式会社 | γ−ＡＮＰを認識するモノクローナル抗体 |
| JPH0720857B2 (ja) | 1988-08-11 | 1995-03-08 | テルモ株式会社 | リポソームおよびその製法 |
| IT1229514B (it) | 1989-01-30 | 1991-09-03 | Farmhispania S A A Montme | Glicoconiugati anfifilici sintetici per impiego neurologico. |
| DE69020755T3 (de) | 1989-03-01 | 2000-03-02 | Shionogi & Co | Physiologisch aktives Polypeptid und DNA. |
| US20020086843A1 (en) | 1989-03-01 | 2002-07-04 | Daiichi Pure Chemicals Co., Ltd. | Physiologically active polypeptide and DNA |
| US5342940A (en) * | 1989-05-27 | 1994-08-30 | Sumitomo Pharmaceuticals Company, Limited | Polyethylene glycol derivatives, process for preparing the same |
| DK0479948T3 (da) | 1989-06-23 | 1999-05-25 | Genentech Inc | Sammensætninger og fremgangsmåder til syntese af natriuretisk protein-receptor B og anvendelsesfremgangsmåder |
| US5108568A (en) * | 1989-07-07 | 1992-04-28 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Controlled method of reducing electrophoretic mobility of macromolecules, particles or cells |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| SE8904407L (sv) | 1989-12-29 | 1991-06-30 | Qingpingfeng | Medikament foer behandling av hjaertsvikt |
| IE912365A1 (en) * | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| US5202239A (en) | 1990-08-07 | 1993-04-13 | Scios Nova Inc. | Expression of recombinant polypeptides with improved purification |
| JP3026354B2 (ja) | 1990-09-27 | 2000-03-27 | 壽之 松尾 | ヒトｃｎｐ遺伝子及び前駆体蛋白 |
| US5853746A (en) | 1991-01-31 | 1998-12-29 | Robert Francis Shaw | Methods and compositions for the treatment and repair of defects or lesions in cartilage or bone using functional barrier |
| ATE253639T1 (de) | 1991-08-19 | 2003-11-15 | Daiichi Suntory Pharma Co Ltd | Verfahren zur herstellung von peptiden |
| JP2665850B2 (ja) | 1991-11-14 | 1997-10-22 | 塩野義製薬株式会社 | ｈＢＮＰのＣ端を認識するモノクロ−ナル抗体 |
| GB9211686D0 (en) | 1992-06-03 | 1992-07-15 | Medisinsk Innovation A S | Chemical compounds |
| CA2188143A1 (en) | 1992-12-09 | 1995-11-02 | Wolf-Georg Forssmann | Use of brain natriuretic peptides (bnp), phosphorylated urodilatine, phosphorylated cdd/anp and combinations thereof |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| US6191105B1 (en) * | 1993-05-10 | 2001-02-20 | Protein Delivery, Inc. | Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin |
| US5359030A (en) * | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5512459A (en) * | 1993-07-20 | 1996-04-30 | Bionebraska, Inc. | Enzymatic method for modification or recombinant polypeptides |
| AU7655494A (en) | 1993-08-28 | 1995-03-22 | University Of Sheffield, The | Treatment of laminitis |
| US6525022B1 (en) | 1993-11-12 | 2003-02-25 | Genentech, Inc. | Receptor specific atrial natriuretic peptides |
| US6037145A (en) | 1994-09-07 | 2000-03-14 | Suntory Limited | Process for production of protein |
| NO319913B1 (no) * | 1994-12-09 | 2005-10-03 | Shionogi & Co | Fremgangsmate til sandwichimmunoassay for N-peptid |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| EP0856026A1 (de) | 1995-10-19 | 1998-08-05 | Receptagen Corporation | Polyethylenglycolen mit diskreter länge |
| ATE297950T1 (de) * | 1996-03-04 | 2005-07-15 | Scios Inc | Testverfahren und reagenzien zur quantifizierung von hbnp |
| ES2201287T5 (es) | 1996-03-22 | 2007-10-16 | Curis, Inc. | Metodo para mejorar la recuperacion funcional de la coordinacion motora, del habla o la percepcion sensorial tras una isquemia o trauma del sistema nervioso central. |
| US6028055A (en) | 1996-10-22 | 2000-02-22 | Genetech, Inc. | Receptor selective BNP |
| EP0939770A1 (de) | 1996-10-22 | 1999-09-08 | Genentech, Inc. | Rezeptor spezifische bnp |
| WO1998045329A1 (en) | 1997-04-04 | 1998-10-15 | Novo Nordisk A/S | Natriuretic peptide derivatives |
| US20040005669A1 (en) * | 1997-08-07 | 2004-01-08 | Stefan Stahl | Recombinant expression of insulin C-peptide |
| GB9716790D0 (en) | 1997-08-07 | 1997-10-15 | Creative Peptides Sweden Ab | Recombinant DNA molecules comprising multimeric copies of a gene sequence and expression thereof |
| US6013630A (en) | 1997-08-21 | 2000-01-11 | Curagen Corporation | Atrial natriuretic factor mutants and ischemic stroke |
| AU751660B2 (en) | 1997-10-24 | 2002-08-22 | Shionogi & Co., Ltd. | Method for inhibiting decomposition of natriuretic peptides and improved method for assaying natriuretic peptides with the use of the same |
| US6495514B1 (en) * | 1998-01-21 | 2002-12-17 | Mercer University | Method for reducing inflammation and inducing an analgesic effect and compounds thereof |
| WO1999046283A1 (en) * | 1998-03-09 | 1999-09-16 | Zealand Pharmaceuticals A/S | Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| US6117644A (en) * | 1998-06-04 | 2000-09-12 | Ottawa Heart Institute Research Corporation | Predicting and detecting cardiac allograft rejection |
| US6703381B1 (en) * | 1998-08-14 | 2004-03-09 | Nobex Corporation | Methods for delivery therapeutic compounds across the blood-brain barrier |
| SE9802946D0 (sv) | 1998-09-02 | 1998-09-02 | Europrofil Ab | Förfarande och listarrangemang för att täcka skarvar eller skapa övergångar i samband med ytbeläggningar |
| JP3799465B2 (ja) * | 1998-09-28 | 2006-07-19 | 参天製薬株式会社 | ナトリウム利尿ペプチドを有効成分とする涙液分泌促進または角結膜障害治療用点眼剤 |
| ATE220917T1 (de) | 1999-01-26 | 2002-08-15 | Lilly Co Eli | Monodisperse formulierungen, die hexamere acylierte insulinanaloge enthalten |
| WO2004011498A2 (en) | 2002-07-31 | 2004-02-05 | Conjuchem Inc. | Long lasting natriuretic peptide derivatives |
| AU765753B2 (en) * | 1999-05-17 | 2003-09-25 | Conjuchem Biotechnologies Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| WO2000071576A2 (en) | 1999-05-24 | 2000-11-30 | Mayo Foundation For Medical Education And Research | Adenovirus vectors encoding brain natriuretic peptide |
| US6309633B1 (en) * | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
| KR100345214B1 (ko) * | 1999-08-17 | 2002-07-25 | 이강춘 | 생체적합성 고분자가 수식된 펩타이드의 비점막 전달 |
| US6610043B1 (en) * | 1999-08-23 | 2003-08-26 | Bistech, Inc. | Tissue volume reduction |
| US6713454B1 (en) * | 1999-09-13 | 2004-03-30 | Nobex Corporation | Prodrugs of etoposide and etoposide analogs |
| US6541508B2 (en) * | 1999-09-13 | 2003-04-01 | Nobex Corporation | Taxane prodrugs |
| US7127290B2 (en) | 1999-10-01 | 2006-10-24 | Cardiac Pacemakers, Inc. | Cardiac rhythm management systems and methods predicting congestive heart failure status |
| US6638906B1 (en) * | 1999-12-13 | 2003-10-28 | Nobex Corporation | Amphiphilic polymers and polypeptide conjugates comprising same |
| US6407211B1 (en) | 1999-12-17 | 2002-06-18 | Mayo Foundation For Medical Education And Research | Chimeric natriuretic peptides |
| JP4237375B2 (ja) * | 2000-03-31 | 2009-03-11 | アスビオファーマ株式会社 | 虚血性疾患の処置又は予防に用いる医薬組成物 |
| DE60115465T2 (de) * | 2000-08-29 | 2006-08-03 | Nobex Corp. | Immunoregulierende verbindungen, deren derivate und ihre verwendung |
| US6867183B2 (en) * | 2001-02-15 | 2005-03-15 | Nobex Corporation | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| US7060675B2 (en) * | 2001-02-15 | 2006-06-13 | Nobex Corporation | Methods of treating diabetes mellitus |
| US7632647B2 (en) * | 2001-04-13 | 2009-12-15 | Biosite Incorporated | Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes |
| US20030219734A1 (en) * | 2001-04-13 | 2003-11-27 | Biosite Incorporated | Polypeptides related to natriuretic peptides and methods of their identification and use |
| FR2823993B1 (fr) * | 2001-04-27 | 2003-06-20 | Rhodia Chimie Sa | Dispersion colloidale aqueuse stable, son procede de preparation |
| ATE439588T1 (de) * | 2001-05-04 | 2009-08-15 | Biosite Inc | Diagnostische marker für akute herzerkrankungen und verfahren des gebrauchs |
| US6828297B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6713452B2 (en) * | 2001-06-04 | 2004-03-30 | Nobex Corporation | Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6835802B2 (en) * | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
| US6828305B2 (en) * | 2001-06-04 | 2004-12-07 | Nobex Corporation | Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US7713932B2 (en) * | 2001-06-04 | 2010-05-11 | Biocon Limited | Calcitonin drug-oligomer conjugates, and uses thereof |
| US6858580B2 (en) * | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
| US6737913B2 (en) * | 2001-06-15 | 2004-05-18 | Silicon Laboratories, Inc. | Differential mode circuitry and method of calibrating same without matched external current sources |
| US7196059B2 (en) * | 2001-09-07 | 2007-03-27 | Biocon Limited | Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith |
| US6770625B2 (en) * | 2001-09-07 | 2004-08-03 | Nobex Corporation | Pharmaceutical compositions of calcitonin drug-oligomer conjugates and methods of treating diseases therewith |
| US7030082B2 (en) * | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
| ATE446971T1 (de) | 2001-09-07 | 2009-11-15 | Biocon Ltd | Verfahren zur synthese von insulinpolypeptid- oligomer-konjugaten und proinsulinpolypeptid- oligomer-konjugaten und verfahren zu deren synthese |
| US6913903B2 (en) * | 2001-09-07 | 2005-07-05 | Nobex Corporation | Methods of synthesizing insulin polypeptide-oligomer conjugates, and proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| US7312192B2 (en) * | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
| AU2003214210A1 (en) * | 2002-03-18 | 2003-10-08 | Scios Inc. | Treatment of congestive heart failure with natriuretic peptide and a diuretic |
| AU2003285200A1 (en) | 2002-11-09 | 2004-06-03 | Nobex Corporation | Modified carbamate-containing prodrugs and methods of synthesizing same |
| DE60331584D1 (de) | 2002-11-26 | 2010-04-15 | Biocon Ltd | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen |
| US20060198819A1 (en) * | 2003-08-08 | 2006-09-07 | Novo Nordisk Healthcare A/G | Use of galactose oxidase for selective chemical conjugation of protractor molecules to proteins of therapeutic interest |
-
2003
- 2003-11-12 DE DE60331584T patent/DE60331584D1/de not_active Expired - Lifetime
- 2003-11-12 BR BR0316560-4A patent/BR0316560A/pt not_active IP Right Cessation
- 2003-11-12 EP EP03812053A patent/EP1569683B1/de not_active Expired - Lifetime
- 2003-11-12 CN CNB2003801091794A patent/CN100558398C/zh not_active Expired - Fee Related
- 2003-11-12 AU AU2003297583A patent/AU2003297583B2/en not_active Ceased
- 2003-11-12 AT AT03812053T patent/ATE459370T1/de not_active IP Right Cessation
- 2003-11-12 WO PCT/US2003/037996 patent/WO2004047871A2/en active Application Filing
- 2003-11-12 PL PL377813A patent/PL377813A1/pl not_active Application Discontinuation
- 2003-11-12 CA CA002504287A patent/CA2504287A1/en not_active Abandoned
- 2003-11-12 SG SG200703827-6A patent/SG159387A1/en unknown
- 2003-11-26 US US10/723,933 patent/US7662773B2/en not_active Expired - Fee Related
- 2003-11-26 JP JP2004555809A patent/JP2006515579A/ja active Pending
-
2006
- 2006-07-04 HK HK06107556.5A patent/HK1087327A1/xx not_active IP Right Cessation
-
2010
- 2010-04-13 AU AU2010201455A patent/AU2010201455A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN100558398C (zh) | 2009-11-11 |
| US20040203081A1 (en) | 2004-10-14 |
| EP1569683B1 (de) | 2010-03-03 |
| JP2006515579A (ja) | 2006-06-01 |
| CN1741814A (zh) | 2006-03-01 |
| WO2004047871A2 (en) | 2004-06-10 |
| ATE459370T1 (de) | 2010-03-15 |
| AU2003297583B2 (en) | 2010-01-14 |
| CA2504287A1 (en) | 2004-06-10 |
| AU2003297583A1 (en) | 2004-06-18 |
| US7662773B2 (en) | 2010-02-16 |
| PL377813A1 (pl) | 2006-02-20 |
| WO2004047871A3 (en) | 2005-03-17 |
| AU2010201455A1 (en) | 2010-05-06 |
| EP1569683A2 (de) | 2005-09-07 |
| BR0316560A (pt) | 2005-10-04 |
| HK1087327A1 (en) | 2006-10-13 |
| SG159387A1 (en) | 2010-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60331584D1 (de) | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen | |
| WO2005116655A3 (en) | Natriuretic compounds, conjugates, and uses thereof | |
| WO2006076471A3 (en) | Bnp conjugates and methods of use | |
| MX2010004547A (es) | Pegilacion por la tecnica de acoplamiento y bloqueo (dnl). | |
| WO2005058958A3 (en) | Novel glp-1 analogues linked to albumin-like agents | |
| KR20090098843A (ko) | 신규 화합물 및 식습관에 대한 이의 효과 | |
| JP2016183192A (ja) | 新規のグルカゴンアナログ | |
| RU2009105696A (ru) | N-концевое полисиалилирование | |
| TWI747929B (zh) | 一種人胰島素或其類似物的醯化衍生物 | |
| RU2014129893A (ru) | Фармацевтическая композиция и способ лечения связанных с гормоном роста заболеваний у человека | |
| RU2015142992A (ru) | Сайт-специфическая конъюгация антитело-лекарственное средство посредством гликоинженерии | |
| NZ599345A (en) | Immunogens from uropathogenic Escherichia Coli | |
| MX2009002999A (es) | Analogos de insulina resistentes a proteasa. | |
| WO2009158704A3 (en) | Therapeutic agents comprising elastin-like peptides | |
| EA200400565A1 (ru) | Конъюгаты химически модифицированного гормона роста человека | |
| NO20021335L (no) | C-peptid for forbedret fremstilling av insulin og insulinanaloger | |
| WO2003076585A3 (en) | Controlled modulation of amino acid side chain length of peptide antigens | |
| JP2015514690A (ja) | 生理活性ポリペプチド複合体の製造のための改善工程 | |
| BRPI0506694A (pt) | análogos de peptìdeo-1 semelhante ao glucagon com longa duração de ação | |
| WO2007005056A3 (en) | Platinum complexes with mononitrile-containing ligands | |
| TW200502251A (en) | Natriuretic compound conjugates, conjugates, and uses thereof | |
| WO2000006185A3 (en) | Methods of using lanreotide, a somatostatin analogue | |
| PE20050285A1 (es) | Composicion farmaceutica que comprende analogos ciclicos de somatostatina | |
| TW200616658A (en) | Endogenously-formed conjugate of albumin | |
| WO2009066245A3 (en) | Thomsen-friedenreich disaccharide modified immunogen (tfd), preparation procedure, compositions comprising it, uses, and treatment methods |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |